KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Operating Margin (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Operating Margin readings, the most recent being 16.37% for Q1 2026.

  • On a quarterly basis, Operating Margin rose 304.0% to 16.37% in Q1 2026 year-over-year; TTM through Mar 2026 was 13.19%, a 1035.0% increase, with the full-year FY2025 number at 12.5%, up 1433.0% from a year prior.
  • Operating Margin hit 16.37% in Q1 2026 for Teva Pharmaceutical Industries, up from 6.37% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 19.69% in Q3 2025 to a low of 25.54% in Q2 2022.
  • Median Operating Margin over the past 5 years was 0.12% (2024), compared with a mean of 0.58%.
  • Biggest five-year swings in Operating Margin: plummeted -4043bps in 2022 and later surged 4116bps in 2023.
  • Teva Pharmaceutical Industries' Operating Margin stood at 24.2% in 2022, then surged by 170bps to 16.96% in 2023, then crashed by -106bps to 1.0% in 2024, then surged by 737bps to 6.37% in 2025, then surged by 157bps to 16.37% in 2026.
  • The last three reported values for Operating Margin were 16.37% (Q1 2026), 6.37% (Q4 2025), and 19.69% (Q3 2025) per Business Quant data.